Glucagon Like Peptide 1 Receptor Agonists for Targeted Delivery of Antisense Oligonucleotides to Pancreatic Beta Cell.

The extra hepatic delivery of antisense oligonucleotides (ASOs) remains a challenge and hampers the widespread application of this powerful class of therapeutic agents. In that regard, pancreatic beta cells are a particularly attractive but challenging cell type because of their pivotal role in diabetes and the fact that they are refractory to uptake of unconjugated ASOs. To circumvent this, we have expanded our understanding of the structure activity relationship of ASOs conjugated to Glucagon Like Peptide 1 Receptor (GLP1R) agonist peptide ligands. We demonstrate the key role of the linker chemistry and its optimization to design maleimide based conjugates with improved in vivo efficacy. In addition, truncation studies and scoping of a diverse set of GLP1R agonists proved fruitful to identify additional targeting ligands efficacious in vivo including native hGLP1(7-36)NH2. Variation of the carrier peptide also shed some light on the dramatic impact of subtle sequence differences on the corresponding ASO conjugate performance in vivo, an area which clearly warrant further investigations. We have confirmed the remarkable potential of GLP1R agonist conjugation for the delivery of ASOs to pancreatic beta cell by effectively knocking down islet amyloid polypeptide (IAPP) mRNA, a potential proapoptotic target, in mice.

Synthesis and evaluation of diphenylphosphinic amides and diphenylphosphine oxides as inhibitors of Kv1.5.

Diphenylphosphinic amides and diphenylphosphine oxides have been synthesized and tested as inhibitors of the Kv1.5 potassium ion channel as a possible treatment for atrial fibrillation. In vitro structure-activity relationships are discussed and several compounds with Kv1.5 IC(50) values of <0.5 µM were discovered. Selectivity over the ventricular IKs current was monitored and selective compounds were found. Results from a rabbit PD-model are included.

Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection.

The mechanism-based risk for hyperkalemia has limited the use of mineralocorticoid receptor antagonists (MRAs) like eplerenone in cardio-renal diseases. Here, we describe the structure and property-driven lead generation and optimization, which resulted in identification of MR modulators ( S)-1 and ( S)-33. Both compounds were partial MRAs but still demonstrated equally efficacious organ protection as eplerenone after 4 weeks of treatment in uni-nephrectomized rats on high-salt diet and aldosterone infusion. Importantly, and in sharp contrast to eplerenone, this was achieved without substantial changes to the urine Na+/K+ ratio after acute treatment in rat, which predicts a reduced risk for hyperkalemia. This work led to selection of ( S)-1 (AZD9977) as the clinical candidate for treating MR-mediated cardio-renal diseases, including chronic kidney disease and heart failure. On the basis of our findings, we propose an empirical model for prediction of compounds with low risk of affecting the urinary Na+/K+ ratio in vivo.

Chelation-controlled radical chain reactions studied by electrospray ionization mass spectrometry.

Electrospray ionization mass spectrometry (ESI-MS) is a novel tool for the investigation of chemical reactions in solution and for the direct detection and identification of reactive intermediates. The tributyltin hydride mediated addition of tert-butyl iodide to dimethyl 2-cyclohexyl-4-methyleneglutarate (2) in the presence of Lewis acids was investigated by ESI-MS using a microreactor coupled on-line to an ESI mass spectrometer. For the first time we have been able to show that transient radicals in radical chain reactions can be detected unambiguously under steady-state conditions in the reaction solution and can be characterized by ESI-MS/MS and accurate mass determination. The detection of different heterodimer radical complexes by ESI-MS/MS has provided new insights into the mechanism of Lewis acid controlled radical chain reactions. Dimeric chelate complexes of glutarates, such as 2 and 3, and Lewis acids, like Sc(OTf)3, MgBr2OEt2 and LiClO4, were observed as well as higher aggregates with additional equivalents of Lewis acid. Evidence for a dynamic equilibrium of the complexes in solution was found by NMR spectroscopy. The ESI-MS investigation of the chelation of glutarate 2 with various Lewis acids has led to the conclusion that the tendency for Lewis acids to form dimeric chelate complexes and higher aggregates has an important effect on the stereoselective outcome of the radical reactions.